E Ink logo

E Ink

North America, Massachusetts, United States, Cambridge

Description

E Ink manufactures a type of electronic paper based on research started at the MIT Media Lab.

Investor Profile

E Ink has made 3 investments, with 2 in the past 12 months and 0% as lead.

Stage Focus

  • Seed (33%)
  • Series B (33%)
  • Series C (33%)

Country Focus

  • United Kingdom (100%)

Industry Focus

  • Biotechnology
  • Life Science
  • Pharmaceutical
  • Health Care
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does E Ink frequently co-invest with?

Co-Investments: 1
G. K. Goh
Asia, Central Region, Singapore, Singapore
Co-Investments: 1
Raw Ventures
Europe, England, United Kingdom, London
Co-Investments: 1
KHP Ventures
Europe, England, United Kingdom, London
Co-Investments: 1
UK Innovation & Science Seed Fund
Europe, Oxfordshire, United Kingdom, Harwell
Co-Investments: 1
British Business Bank
Europe, Sheffield, United Kingdom, Sheffield
Co-Investments: 1
QantX
Europe, Devon, United Kingdom, Exeter
Co-Investments: 1
Kadmos Capital
Europe, England, United Kingdom, London
Co-Investments: 1
Future Planet Capital
Europe, England, United Kingdom, London
Co-Investments: 1
Amadeus Capital Partners
Europe, Cambridgeshire, United Kingdom, Cambridge
Co-Investments: 1

Which angels does E Ink often collaborate with?

JM
North America, Massachusetts, United States, Cambridge
Shared Deals: 1

What are some of recent deals done by E Ink?

iFast Diagnostics

Northampton, Northamptonshire, United Kingdom

iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

Health Care
SeedNov 4, 2024
Amount Raised: $6,477,154
Nuclera

Cambridge, Cambridgeshire, United Kingdom

Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers.

BiotechnologyLife SciencePharmaceutical
Series COct 15, 2024
Amount Raised: $75,000,000
Nuclera

Cambridge, Cambridgeshire, United Kingdom

Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers.

BiotechnologyLife SciencePharmaceutical
Series BFeb 2, 2022
Amount Raised: $42,500,000